While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace fulvestrant.

Incomplete applications will not be reviewed until all documentation is received. Learn from leaders in clinical immunology from the NHS across the UK and leading researchers from the Lydia Becker ...